Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol

Respiratory Research

Volumn 18, Issue 1, 2017, Pages

  Singh, Dave ^a   D'Urzo, Anthony D ^b   Chuecos, Ferran ^c   Muñoz, Anna ^c   Garcia Gil, Esther ^c  

^a MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF TORONTO   (Canada)

^c ASTRAZENECA   (United Kingdom)

Author keywords

Bronchodilation; Chronic respiratory disease; COPD; LABA; LAMA

Indexed keywords

ACLIDINIUM BROMIDE PLUS FORMOTEROL FUMARATE; CORTICOSTEROID; PLACEBO; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; FORMOTEROL FUMARATE; MUSCARINIC RECEPTOR BLOCKING AGENT; TROPANE DERIVATIVE;

ADULT; AIRWAY; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICALLY IMPORTANT DETERIORATION; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRY POWDER INHALER; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HEALTH STATUS; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; ST. GEORGE RESPIRATORY QUESTIONNAIRE; TREATMENT RESPONSE; CLINICAL TRIAL; DETERIORATION; DRUG COMBINATION; DRUG EFFECT; LUNG; MIDDLE AGED; PATHOPHYSIOLOGY; QUESTIONNAIRE; SEVERITY OF ILLNESS INDEX; TIME FACTOR; TREATMENT OUTCOME;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; BRONCHODILATOR AGENTS; CLINICAL DETERIORATION; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; FORCED EXPIRATORY VOLUME; FORMOTEROL FUMARATE; HUMANS; LUNG; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX; SURVEYS AND QUESTIONNAIRES; TIME FACTORS; TREATMENT OUTCOME; TROPANES;

EID: 85019685686     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/s12931-017-0583-0     Document Type: Article

References (15)

1. Calverley P, Bellamy D. The challenge of providing better care for patients with chronic obstructive pulmonary disease: the poor relation of airways obstruction? Thorax. 2000;55:78-82.
2. Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. Eur Respir J. 2017;49:1700214. [ https://doi.org/10.1183/13993003.00214-2017 ].
3. Beeh KM, Korn S, Beier J, Jadayel D, Henley M, D'Andrea P, et al. Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT study. Respir Med. 2014;108:584-92.
4. D'Urzo AD, Rennard SI, Kerwin EM, Mergel V, Leselbaum AR, Caracta CF. Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study. Respir Res. 2014;15:123-41.
5. Rabe KF, Timmer W, Sagkriotis A, Viel K. Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD. Chest. 2008;134:255-62.
6. Singh D, Jones PW, Bateman ED, Korn S, Serra C, Molins E, et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study. BMC Pulm Med. 2014;14:178-89.
7. Tashkin DP, Ferguson GT. Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease. Respir Res. 2013;14:49.
8. Wedzicha JA, Decramer M, Ficker JH, Niewoehner DE, Sandstrom T, Taylor AF, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med. 2013;1:199-209.
9. Buhl R, Maltais F, Abrahams R, Bjermer L, Derom E, Ferguson G, et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4). Eur Respir J. 2015;45:969-79.
10. Maltais F, Gáldiz Iturri JB, Kirsten A, Singh D, Hamilton A, Tetzlaff K, et al. P250 Effects of 12 weeks of once-daily tiotropium and olodaterol fixed-dose combination on exercise endurance in patients with COPD [abstract]. Thorax. 2014;69:A186.
11. Singh D, Maleki-Yazdi MR, Tombs L, Iqbal A, Fahy WA, Naya I. Prevention of clinically important deteriorations in COPD with umeclidinium/vilanterol. Int J Chron Obstruct Pulmon Dis. 2016;11:1413-24.
12. Jones PW, Lamarca R, Chuecos F, Singh D, Agustí A, Bateman ED, et al. Characterisation and impact of reported and unreported exacerbations: results from ATTAIN. Eur Respir J. 2014;44:1156-65.
13. Donohue JF. Minimal clinically important differences in COPD lung function. COPD. 2005;2:111-24.
14. Jones PW. St. George's respiratory questionnaire: MCID. COPD. 2005;2:75-9.
15. Witek Jr TJ, Mahler DA. Minimal important difference of the transition dyspnoea index in a multinational clinical trial. Eur Respir J. 2003;21:267-72.